B (2021)
Early case series and open-label studies support feasibility and biological plausibility, whereas randomized trials show mixed clinical signals, highlighting donor-dependent effects, protocol heterogeneity (preconditioning, route, dose/frequency), and the need for engraftment-aware endpoints [252,253,254,255]
Genetic personalization outperforms age-based dosing protocols in predicting both efficacy and tolerability
Opciones con bajo contenido de azcar : Productos como LMNT, Ultima Replenisher y Nuun Sport ofrecen formulaciones sin azcar o con contenido mnimo, apropiadas para pacientes con diabetes
Consumption of the non-nutritive sweetener stevia for 12 weeks does not alter the composition of the human gut microbiota
Antioxidant therapy in sepsis